Apellis Pharmaceuticals Inc (APLS) concluded trading on Thursday at a closing price of $20.09, with 4.64 million shares of worth about $93.12 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -33.89% during that period and on July 24, 2025 the price saw a gain of about 0.95%. Currently the company’s common shares owned by public are about 125.66M shares, out of which, 103.40M shares are available for trading.
Stock saw a price change of 0.25% in past 5 days and over the past one month there was a price change of 7.95%. Year-to-date (YTD), APLS shares are showing a performance of -45.78% which decreased to -37.04% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $16.10 but also hit the highest price of $41.94 during that period. The average intraday trading volume for Apellis Pharmaceuticals Inc shares is 2.37 million. The stock is currently trading 6.22% above its 20-day simple moving average (SMA20), while that difference is up 9.16% for SMA50 and it goes to -19.17% lower than SMA200.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) currently have 125.66M outstanding shares and institutions hold larger chunk of about 100.06% of that.
The stock has a current market capitalization of $2.52B and its 3Y-monthly beta is at 0.76. It has posted earnings per share of -$1.79 in the same period. It has Quick Ratio of 3.62 while making debt-to-equity ratio of 2.86. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APLS, volatility over the week remained 5.02% while standing at 4.52% over the month.
Analysts are in expectations that Apellis Pharmaceuticals Inc (APLS) stock would likely to be making an EPS of -0.48 in the current quarter, while forecast for next quarter EPS is 0.11 and it is -0.9 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.6 which is -0.27 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.29 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -19.51% while it is estimated to increase by 63.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on May 09, 2025 offering an Outperform rating for the stock and assigned a target price of $52 to it. Coverage by BofA Securities stated Apellis Pharmaceuticals Inc (APLS) stock as a Neutral in their note to investors on May 09, 2025, suggesting a price target of $23 for the stock. On April 29, 2025, Cantor Fitzgerald Initiated their recommendations, while on December 17, 2024, Goldman Downgrade their ratings for the stock with a price target of $36. Stock get an Equal-weight rating from Morgan Stanley on November 21, 2024.
